IL6RA Specific Neutra™ Antibody Products

Are prolonged drug development timelines or inefficient IL-6 pathway modulation hindering your autoimmune or oncology research? Creative Biolabs’ IL6RA specific Neutra™ antibody products leverage advanced recombinant antibody engineering and high-affinity epitope mapping to enable robust blockade of pathogenic IL-6 signaling, streamlining therapeutic discovery and validation.

Introduction to IL6RA

Interleukin 6 receptor alpha (IL6RA) is a transmembrane glycoprotein and key component of the IL-6 signaling complex. It binds IL-6 with low affinity, forming a hexameric complex with the signal-transducing protein gp130 to initiate downstream cascades. IL6RA is expressed on hepatocytes, leukocytes, and activated endothelial cells, playing pivotal roles in acute-phase responses, immune regulation, and hematopoiesis. Dysregulation of IL6RA-mediated signaling is implicated in chronic inflammation, autoimmunity, and cancer progression.

• Structure

IL6RA comprises an extracellular domain with three distinct regions: an immunoglobulin (Ig)-like domain for ligand binding, a cytokine-binding module, and a fibronectin type III (FNIII) domain critical for gp130 interaction. The transmembrane helix anchors the receptor, while the short cytoplasmic tail lacks intrinsic kinase activity, relying on gp130 for signal transduction. Structural studies reveal that IL6RA undergoes conformational changes upon IL-6 binding, enabling hexameric assembly and JAK/STAT activation.

• Related Signaling Pathways

IL6RA activates two primary pathways:

- Classic signaling: Membrane-bound IL6RA recruits gp130, triggering JAK/STAT3 activation, which drives pro-inflammatory gene expression (e.g., CRP, fibrinogen).

- Trans-signaling: Soluble IL6RA (sIL6RA), generated via alternative splicing or proteolytic cleavage, complexes with IL-6 and gp130 to hyperactivate endothelial and immune cells, amplifying inflammation in pathologies like rheumatoid arthritis (RA) and cytokine storm syndrome.

Fig.1 Two modes of IL-6R signaling and their associated intracellular pathways.¹

• Associated Diseases

IL6RA hyperactivity is central to autoimmune disorders (e.g., RA, Crohn's disease), inflammatory conditions (e.g., Castleman's disease), and cancers (e.g., multiple myeloma). Elevated sIL6RA levels correlate with poor prognosis in COVID-19-related acute respiratory distress and metastatic cancers.

Therapeutic Applications of IL6RA Neutralizing Antibodies

• Autoimmune Disease Management

Anti-IL6RA antibodies ameliorate RA and juvenile idiopathic arthritis by blocking synovial inflammation and joint destruction. Clinical trials show rapid reduction in Disease Activity Score-28 (DAS-28) and radiographic progression.

• Oncology and Cachexia

In multiple myeloma, IL6RA inhibition disrupts tumor cell proliferation and osteoclast activation. Antibodies also reverse cancer-related cachexia by restoring muscle protein synthesis via STAT3 downregulation.

• Cytokine Storm Intervention

IL6RA-targeted therapy mitigates life-threatening hyperinflammation in COVID-19 and CAR-T cell-induced cytokine release syndrome (CRS), reducing ventilator dependence and mortality.

• Chronic Inflammatory Condition

Anti-IL6RA agents improve outcomes in Crohn's disease and uveitis by normalizing Th17/Treg balance and reducing intestinal permeability.

Our Anti-IL6RA Antibodies

Neutralizing antibodies targeting IL6RA inhibit pathogenic signaling while preserving homeostatic IL-6 functions. Creative Biolabs' IL6RA specific antibodies are engineered for:

• High Specificity: Selective binding to the IL-6 interaction site or gp130 docking interface, preventing hexamer formation.
• Dual Blockade: Simultaneous inhibition of classic and trans-signaling pathways.
• Enhanced Pharmacokinetics: Fc modifications extend serum half-life, optimizing therapeutic dosing.

Validated in preclinical models, these antibodies demonstrate superior efficacy in suppressing STAT3 phosphorylation and reducing inflammatory biomarkers compared to conventional inhibitors.

Creative Biolabs delivers rigorously validated IL6RA specific Neutra™ antibodies, empowering researchers to overcome therapeutic development bottlenecks. Contact our team today to discuss custom solutions for your autoimmune or oncology program.

REFERENCE

1. Villar-Fincheira, Paulina, et al. "Role of interleukin-6 in vascular health and disease." Frontiers in molecular biosciences 8 (2021): 641734. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fmolb.2021.641734